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Effects of immunomodulatory treatment
with subcutaneous interferon beta-1a
oncognitive decline in mildly disabled
patients with relapsing–remitting multiple
sclerosis
F Patti1, MP Amato2, S Bastianello3, L Caniatti4, E Di Monte5,
P Ferrazza6, B Goretti2, P Gallo7, V Brescia Morra8, S Lo
Fermo1, O Picconi9, MR Tola4, M Trojano5 and on behalf of the
COGIMUS Study Group
Abstract
The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNb-1a) on cognition in
mildly disabled patients with relapsing–remitting multiple sclerosis (RRMS). Patients aged 18–50 years with RRMS
(McDonald criteria; Expanded Disability Status Scale score 4.0) were assigned IFNb therapy at the physician’s discretion
and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the
baseline and regular intervals for up to three years.
This analysis included 459 patients who received sc IFNb-1a (44mcg: n¼ 236; 22mcg: n¼ 223; three-year follow up
was available for 318 patients). The hazard ratio for cognitive impairment over three years (44mcg versus 22mcg)
was 0.68 (95% confidence interval [CI]: 0.480–0.972), suggesting a 32% lower risk with the higher dose treatment.
At year 3, the proportion of patients who were cognitively impaired increased slightly from 23.5% at the baseline to
24.8% in the IFNb-1a 22mcg treatment group, but remained stable at 15.2% in the IFNb-1a 44mcg treatment group.
The proportion of patients with cognitive impairment at year 3 was significantly higher in the 22mcg group than in the
44mcg group (P¼ 0.03), although a trend was also seen at the baseline (P¼ 0.058). Multivariate logistic regression
(corrected for baseline cognitive deficits) indicated that treatment with the higher dose of IFNb-1a was predictive of
lower cognitive impairment at three years (odds ratio: 0.51, 95% CI: 0.26–0.99) compared with the lower dose of
IFNb-1a.
These findings suggest that sc IFNb-1a may have dose-dependent cognitive benefits in mildly disabled patients with RRMS,
and may support early initiation of high-dose IFNb-1a treatment.
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Introduction
Cognitive impairment is a common symptom of multi-
ple sclerosis (MS), occurring in approximately 40–65%
of patients with MS.1 Cognitive deﬁcits may develop in
all MS subtypes and at any disease stage,2,3 including
in patients without physical disability4 or with clinically
isolated syndrome.5,6 Memory, learning, attention and
information-processing activities are most commonly
aﬀected by MS, which may reﬂect damage to speciﬁc
brain areas. Impaired cognitive function can cause
considerable disability in MS, independent of physical
symptoms, and contributes to a poor quality of life
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(QoL).7 In addition, fatigue and depression are
common comorbidities of cognitive impairment and
can further increase disability levels.8
Although little is known about the natural history of
cognitive impairment in MS, available data suggest that
remission of cognitive symptoms is unlikely and that
cognitive performance decreases with worsening dis-
ability.9,10 Cognitive impairment may also predict phys-
ical disability or indicate progressive disease in the
absence of worsening physical symptoms.11
Despite the high prevalence of cognitive impairment
in MS, it is rarely assessed during routine patient man-
agement. Furthermore, treatment for cognitive impair-
ment centres on symptomatic therapies, with few
pharmacological options. The observation that some
magnetic resonance imaging (MRI) disease measures,
including lesion load and brain volume,1 correlate with
cognitive impairment, suggests that disease-modifying
drugs (DMDs) that reduce lesion development may
also prevent or delay cognitive decline. However, the
potential cognitive beneﬁts of DMDs in patients with
MS are unconﬁrmed.12,13
The COGIMUS (COGnitive Impairment in
MUltiple Sclerosis) study was performed to evaluate
the progression of cognitive decline in patients with
early relapsing–remitting MS (RRMS) receiving treat-
ment with interferon beta-1a (IFNb-1a), 22 or 44mcg
(Rebif, Merck Serono S.A. – Geneva, Switzerland),
administered subcutaneously (sc) three times weekly
(tiw). Here, we report three-year cognition and clinical
results from the study; two-year outcomes have been
reported elsewhere.14
Methods
The COGIMUS study is a prospective, multicentre,
observational, three-year cohort trial assessing cogni-
tive function in Italian patients with RRMS treated
with IFNb. Study enrolment started in September
2003 at the University of Catania, and in January
2004 at the other participating centres, and was com-
pleted in March 2005.
Patients
Eligibility criteria have been described in detail else-
where.15 Brieﬂy, patients aged 18–50 years with a diag-
nosis of RRMS, according to the McDonald criteria16
and an Expanded Disability Status Scale (EDSS)17
score of 4.0, who were naı¨ve to DMD treatment
and had not been taking corticosteroids in the prior
60 days, immunosuppressants in the prior six months,
or other immunomodulators in the previous year, were
eligible for the study. All patients at the 40 study
centres who fulﬁlled the inclusion and exclusion criteria
were invited to participate in the study. In accordance
with Italian law, patients were not paid for participat-
ing in this study. Patients were not seeking neuropsy-
chological (NPS) consultation for suspected cognitive
problems, but were motivated to participate by the
potential beneﬁts of undergoing evaluations that
would not be performed as part of routine clinical prac-
tice. All patients gave written informed consent prior to
undergoing any tests not performed as part of their
routine management.
Treatment
Patients were assigned IFNb treatment (sc IFNb-1a, 22
or 44mcg tiw [Rebif]; intramuscular [im] IFNb-1a,
30mcg once weekly [qw: Avonex, Biogen Idec Inc,
Cambridge, MA, USA]; or sc interferon beta-1a
[IFNb-1b], 250mcg every other day [Betaferon, Bayer
Schering Pharma AG, Berlin, Germany]) at the discre-
tion of the treating physician. A total of 550 patients
were enrolled into the study. Of these patients,
459 (83.5%) received treatment with sc IFNb-1a:
223 (40.5%) received 22mcg tiw and 236 (42.9%)
received 44mcg tiw; 64 patients (11.6%) were treated
with im IFNb-1a and 27 patients (4.9%) with sc
IFNb-1b. At three years, only 13 patients receiving im
IFNb-1a and 19 patients receiving sc IFNb-1b were
available for follow up. As only a small proportion of
patients in this observational study were assigned treat-
ment with sc IFNb-1b or im IFNb-1a, and several
dropped out over the three years, it was more appropri-
ate to compare outcomes between the groups of patients
receiving the two doses of sc IFNb-1a than in all four
study groups. The two groups of patients receiving sc
IFNb-1a were of a similar sample size and represented
the majority of the study population (83.5%); therefore,
the analyses focused on outcomes in these 459 patients.
Relapses were treated with corticosteroids and ﬂu-
like symptoms (FLS) were treated with non-steroidal
anti-inﬂammatory drugs or paracetamol. Concomitant
therapies were recorded on the case-report form.
DMDs other than the study drug were not permitted.
Evaluation of disease status
Patients underwent a baseline neurological examination
to determine physical disability (EDSS score), and clin-
ical history was recorded. In two-thirds of the partici-
pating centres, conventional, standardized brain MRI
(1.5 Tesla scanner) was performed at the baseline to
determine T1 gadolinium-enhancing, T1 hypointense
and T2 hyperintense lesion volumes, grey and white
matter volumes and total brain volume. Baseline MRI
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ﬁndings and correlations with cognitive impairment
have been described elsewhere.15 Clinical assessments
(EDSS score and relapses) were repeated and safety
data were collected every six months.
Neuropsychological evaluation
All patients underwent NPS evaluation at the baseline
and every 12 months for three years. If patients were
experiencing disease relapse at the time of scheduled
NPS assessments, cognitive testing was delayed until
30 days after the last steroid injection. These assess-
ments included Rao’s Brief Repeatable Battery10 and
the Stroop Colour-Word Task (ST)18 for cognitive
domains (alternate, parallel versions of Rao’s battery
were used to minimize learning eﬀects; alternate ver-
sions were administered in the order A, B, A, B to all
patients), the Hamilton Depression Rating Scale,19 the
MSQoL-54 questionnaire20 for QoL, the Fatigue
Impact Scale21 and the Environmental Status Scale22
for social functioning. Patient intelligence quotient
(IQ) was determined at the baseline by administering
the Brief Intelligence Test,23,24 as described pre-
viously.15 Cognitive impairment was deﬁned as 1 SD
below the mean Italian normative values for each cog-
nitive test, as described previously in a study of 200
healthy volunteers. This normative population had a
mean (SD) age of 41.5 (9.8) years, a male:female ratio
of 1:2, and had spent a mean (SD) of 12.3 (3.6) years in
education.25
A cognitive impairment index was constructed at the
baseline and year 3 for each patient using the mean and
SD from the normative sample of Rao’s battery25 in
order to conﬁrm that cognitive impairment was cor-
rectly detected. A grading system was applied to each
patient’s score on each cognitive test, dependent on the
number of SDs below the normative mean as described
previously.15,26
Study endpoints
The primary endpoint was the proportion of patients
with cognitive impairment over three years in patients
treated with diﬀerent doses of sc IFNb-1a. In the
absence of widely accepted guidelines for the assess-
ment of cognitive function, cognitive impairment was
deﬁned as impaired performance on at least three cog-
nitive tests. This deﬁnition for cognitive impairment has
previously been shown to be sensitive to changes in
cognitive function over time in a study of Italian
patients with early MS, in which cognitive decline was
compared in patients and healthy volunteers over 10
years of follow up.7 In this study population, we
found that the proportion of patients identiﬁed as
having cognitive impairment at the baseline was similar
when using either this deﬁnition or a deﬁnition based
on ﬁfth and 95th percentiles for the Rao’s battery and
the ST, respectively.15
Additional endpoints were the change in cognitive
impairment index score over three years and the assess-
ment of factors predictive of cognitive impairment at
three years. Other endpoints will be reported elsewhere.
Discontinuations were recorded, and patients who dis-
continued treatment were followed up regularly in the
clinical trial setting.
Statistical analyses
Descriptive analyses were performed at the baseline for
the cohort of 459 patients treated with sc IFNb-1a. For
outcome measures at three years, only patients with
three years of follow up were included in the analyses.
No imputation of missing data was considered. The
Cox proportional-hazards model was used to compare
cognitive impairment over three years. A multivariate
regression model was developed by sequentially adding
variables that had a signiﬁcant hazard ratio in the uni-
variate analysis. To account for the fact that all patients
were entered into the analysis, the hazard ratio was
evaluated using ‘more than one time option shared’
(STATA software). Kaplan–Meier survival curves
were constructed to evaluate longitudinal diﬀerences
between treatments.
The following tests were also conducted, with a sig-
niﬁcance level of 0.05. Chi-squared tests were per-
formed to compare proportions. The Mann–Whitney
test was used for the comparison of two independent
samples. The Kazis’ eﬀect was calculated to assess the
variability of the cognitive tests over time, using the
calculation: (mean score at year 3 – mean score at base-
line)/SD at the baseline. A positive result indicated an
improvement and a negative result indicated a worsen-
ing in cognitive function over three years of treatment.
The eﬀect sizes are deﬁned as: small, 0.20–0.49; moder-
ate, 0.50–0.79; and large, 0.80–1.00.27 The Wilcoxon
test for paired samples was performed to evaluate
changes over time in the cognitive impairment index.
Risk factors for cognitive impairment at three years
were identiﬁed using univariate and multivariate logis-
tic regression. Univariate logistic regression was per-
formed for the following variables: the baseline
characteristics shown in Table 1; the presence or
absence of cognitive impairment at the baseline; and
treatment group (IFNb-1a 22 or 44mcg sc tiw). A mul-
tivariate regression model was then developed by
sequentially adding variables with a signiﬁcant odds
ratio in the univariate analysis. Variables that remained
signiﬁcant were included in the ﬁnal model.
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Results
Patients and baseline characteristics
Here we report baseline characteristics and three-year
outcomes from the 459 patients treated with sc IFNb-
1a, of whom 223 (48.6%) received the 22mcg dose and
236 (51.4%) received the 44mcg dose. Descriptive data
for the small subgroups of patients receiving im IFNb-
1a or sc IFNb-1b are also provided.
Among the 459 patients receiving sc IFNb-1a, the
mean (SD) age was 33.3 (8.13) years, and the male:fe-
male ratio was 1:1.87. The mean (SD) duration of dis-
ease was 3.8 (4.47) years and the mean (SD) EDSS
score was 1.8 (1.0). There were no signiﬁcant diﬀerences
Table 1. Baseline demographic characteristics in patients receiving sc IFNb-1a, by treatment group
Treatment group
(IFNb-1a dose sc tiw) n Mean SD P valuea
Age, years 22mcg 223 33.8 8.4 0.259
44mcg 236 32.8 7.9
Years in formal education 22mcg 223 12.2 3.5 0.406
44mcg 236 12.5 3.4
Duration of disease, years 22mcg 223 4.0 4.7 0.374
44mcg 236 3.6 4.3
Total IQ scoreb 22mcg 213 108.8 8.8 0.422
44mcg 232 109.4 8.6
Verbal IQ score 22mcg 213 106.3 11.1 0.308
44mcg 232 106.8 9.1
Performance IQ score 22mcg 213 105.4 9.3 0.746
44mcg 232 106.0 8.9
Physical Health Composite Score 22mcg 223 69.6 16.8 0.313
44mcg 235 68.5 16.3
Mental Health Composite Score 22mcg 223 67.4 19.8 0.255
44mcg 235 65.9 19.1
Fatigue Impact Scale, total score 22mcg 223 25.1 25.5 0.224
44mcg 235 27.2 25.4
Hamilton Depression Rating Scale, total score 22mcg 223 6.7 5.2 0.496
44mcg 235 6.9 4.7
Environmental Status Scale, total score 22mcg 223 1.6 2.8 0.083
44mcg 235 1.6 2.3
EDSS score 22mcg 223 1.8 0.9 0.791
44mcg 236 1.8 1.0
T2 hyperintense lesion volume, mm3 22mcg 118 5615.4 6484.4 0.724
44mcg 129 5909.4 6338.7
T1 hypointense lesion volume (black holes), mm3 22mcg 116 1070.9 1794.1 0.651
44mcg 128 1001.2 1557.4
Gd-enhancing T1 lesion volume, mm3 22mcg 112 35.2 115.8 0.172
44mcg 126 104.6 428.8
Grey matter volume, mm3 22mcg 129 793,460.8 207,618.2 0.489
44mcg 144 801,810.1 178,519.7
White matter volume, mm3 22mcg 129 770,537.2 277,669.3 0.551
44mcg 144 752,233.0 258,394.8
Brain volume, mm3 22mcg 129 1,563,998.0 115614.9 0.533
44mcg 144 1,554,043.1 119,584.3
Gd, gadolinium.
aMann–Whitney test.
bPopulation ‘average’ IQ score: 99–109.
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in the baseline demographics or general, clinical, NPS
or MRI variables between the two treatment groups
(Table 1).
Overall, 331 patients (72.1%) in the subgroup receiv-
ing sc IFNb-1a completed the three-year study: 163
received IFNb-1a, 22mcg tiw, and 168 received
IFNb-1a, 44mcg tiw. With the exception of verbal
IQ, which was signiﬁcantly higher in patients who
stayed on treatment for the duration of the study
than in those who did not (P¼ 0.0465), there were no
signiﬁcant diﬀerences in the baseline demographic, clin-
ical, NPS and MRI characteristics, or in the assigned
treatment between patients who were still under treat-
ment at three years and those who dropped out of the
study prematurely.
Dropout rates were similar in both treatment arms:
60 (26.9%) patients receiving IFNb-1a 22mcg and 68
(28.8%) patients receiving IFNb-1a 44mcg did not
complete the study. Reasons for discontinuing were:
adverse events (AEs), 13 (2.8%) patients; lost to
follow up, 18 (3.9%) patients; protocol violation, 18
(3.9%) patients; lack of eﬃcacy, 18 (3.9%) patients;
pregnancy/planning to conceive, 16 (3.5%) patients;
other, 45 (9.8%) patients. ‘Other’ reasons were predo-
minantly subjective, such as ‘patient decided not to
continue’. There were no discontinuations due to injec-
tion-site reactions (ISRs).
Dropout rates for the subgroups of patients origi-
nally assigned to im IFNb-1a or IFNb-1b were as fol-
lows. A total of 51/64 patients (79.7%) receiving im
IFNb-1a did not complete the study. The reasons for
study discontinuation were: lost to follow up (n¼ 25);
pregnancy (n¼ 4); and switched to another DMD
(n¼ 22). Of the 27 patients assigned sc IFNb-1b treat-
ment, 8 (29.6%) withdrew from the study. Of these,
four were lost to follow up, one withdrew due to preg-
nancy and three switched to another therapy.
Cognitive impairment at baseline
At study entry, 270 of 459 patients (58.8%) receiving sc
IFNb-1a had impaired performance on at least one
cognitive test, 172 (37.5%) patients had impaired per-
formance on at least two tests, and 98 (21.4%) patients
had impaired performance on at least three tests.
Hence, the prevalence of cognitive impairment in this
population was 21.4%. The proportion of patients with
cognitive impairment at the baseline was higher in the
22mcg dose group (24.2%) than in the 44mcg group
(18.6%; P¼ 0.145). A similar trend was seen among the
318 patients for whom three-year cognitive data were
available: at the baseline, 23.5% of these patients
receiving IFNb-1a, 22mcg sc tiw, were cognitively
impaired, compared with 15.2% of patients receiving
IFNb-1a, 44mcg sc tiw (P¼ 0.058).
In the subgroups of patients assigned to im IFNb-1a
or sc IFNb-1b, eight patients (12.5%) and ﬁve patients
(18.5%), respectively, had impaired performance on at
least three tests at the baseline.
Cognitive impairment at three years
Data on cognitive function at three years were available
for 318 patients (22mcg, n¼ 153; 44mcg, n¼ 165). A
Cox proportional-hazards survival analysis was per-
formed for the development of cognitive impairment
over three years (Figure 1), and showed a 32% risk
reduction for treatment with IFNb-1a 44mcg versus
22mcg. Kaplan–Meier survival curves conﬁrmed the
beneﬁts of receiving the higher dose treatment over
time (P¼ 0.0109; Figure 1).
At year 3, the proportion of patients who were cog-
nitively impaired had increased slightly from the base-
line value of 23.5% to 24.8% in the IFNb-1a 22mcg
treatment group, and had remained stable at 15.2% in
the IFNb-1a 44mcg treatment group. Hence, the pro-
portion of patients with cognitive impairment was sig-
niﬁcantly higher in the lower dose treatment group than
in the higher dose treatment group (15.2% versus
24.8%, respectively, P¼ 0.030), although the baseline
trend for a diﬀerence between these two groups must
be considered.
The cognitive impairment index was signiﬁcantly
lower at three years than at the baseline in both treat-
ment groups (Table 2), indicating improved cognitive
function over the course of the study, but there were no
signiﬁcant diﬀerences between the two treatment
groups. The Kazis’ eﬀect for each cognitive test was
calculated for each treatment group (Table 3). Similar
eﬀect sizes were seen for both treatments for all tests,
with the exception of the Symbol Digit Modalities Test
(SDMT; 22mcg: –0.05, 44mcg: 0.20).
In the subgroups of patients assigned to im IFNb-1a
or sc IFNb-1b, the proportions of patients who were
cognitively impaired at year 3 had increased from the
baseline value in each group: from 12.5 to 23% in the
im IFNb-1a group and from 18.5 to 26% in the sc
IFNb-1b group. However, no further statistical analy-
ses were performed due to the limited numbers of
patients in these subgroups.
Predictors of cognitive impairment at three years
Variables that were signiﬁcant in the univariate logistic
regression were treatment, verbal IQ at the baseline and
impaired cognitive function at the baseline, and these
were included in the multivariate model. Multivariate
logistic regression showed that, after correcting for
baseline cognitive impairment, treatment with higher
dose IFNb-1a and higher verbal IQ at the baseline
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were associated with a lower risk of cognitive impair-
ment at year 3 (Table 4). In addition, the model showed
that impaired cognitive function at the baseline was a
risk factor for cognitive impairment at year 3 (Table 4).
Clinical outcomes
At year 3, complete clinical data were available for 331
patients. Sustained EDSS progression occurred in 55 of
331 (16.6%) patients. Relapse data were available for
428 (93.2%) patients at year 1, 394 (85.8%) patients at
year 2, and 376 (81.9%) patients at year 3. Over the
three-year study period, the mean relapse rate was 0.23
relapses per patient, and 62% of patients remained free
from relapse. No signiﬁcant diﬀerences were found
between the two treatment groups (data not shown).
Safety
The most common AEs reported over the three-year
study were consistent with the known safety proﬁle of
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Figure 1. Kaplan–Meier survival curves for the proportion of patients with 3 impaired cognitive tests during the three-year study,
by treatment. The Cox proportional-hazards model showed that treatment and Physical Health Composite Scores (PHCS) were
significant factors over three years. The hazard ratio (95% confidence interval) for sc IFNb-1a, 22mcg tiw, versus 44mcg sc tiw was
0.68 (0.480–0.972; P¼ 0.0109) and for PHCS was 0.98 (0.98–0.99; not shown).
Table 3. Effect size (Kazis’ effect) for individual cognitive tests
in patients treated with IFNb-1a, 22 or 44mcg sc tiw, for three
years. Positive numbers indicate improved test performance;
effect sizes of 0.20 or above indicate a small effect
Treatment group
Cognitive test
IFNb-1a 22mcg
sc tiw (n¼ 153)
IFNb-1a 44mcg
sc tiw (n¼ 165)
SRT–LTS 0.36 0.39
SRT–CLTR 0.18 0.25
SPART 0.26 0.34
SDMT –0.05 0.20
PASAT-30 0.20 0.29
PASAT-20 0.18 0.20
SRT-D 0.27 0.21
SPART-D 0.29 0.14
WLG –0.26 –0.23
PASAT-20, 20-second Paced Auditory Serial Addition Test; PASAT-30, 30-
second PASAT; SDMT, Symbol Digit Modalities Test; SPART, Spatial
Recall Test; SPART-D, SPART-Delayed; SRT–CLTR, Selective Reminding
Test–Consistent Long-Term Retrieval; SRT-D, SRT-Delayed; SRT–LTS,
SRT–Long-Term Storage; WLG, Word-List Generation.
Table 2. Improvement in cognitive impairment index over
three years in patients treated with IFNb-1a, 22mcg or
44mcg sc tiw
Treatment
Cognitive impairment
index
group Timepoint n Mean SD P valuea
IFNb-1a,
22mcg sc tiw
Baseline 153 9.27 5.948 <0.001
Year 3 153 7.75 5.618
IFNb-1a,
44mcg sc tiw
Baseline 165 8.22 4.858 <0.001
Year 3 165 6.75 4.880
aWilcoxon test.
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IFNb-1a,28,29 and included ISRs, FLS, headache,
depression and laboratory abnormalities.
Discussion
In this study, the proportion of patients with impaired
cognitive function over the three years remained stable,
suggesting that treatment with IFNb-1a, 22 or 44mcg sc
tiw may prevent cognitive decline. Despite the fact that
this study did not include an untreated control group,
making it impossible to determine to what extent IFNb-
1a prevented cognitive decline, cognitive deterioration
over time has been reported in patients with MS, par-
ticularly those with existing cognitive impairment.7
Longitudinal studies of cognitive impairment in MS
are rare. In addition, diﬀerences in study design, patient
populations and deﬁnitions of cognitive impairment,
and the inclusion of patients receiving active treat-
ment,1 make it diﬃcult to describe the natural history
of MS-related cognitive decline. The ﬁndings of three
studies (which included healthy volunteers as a control
group) indicate that declining cognitive function can be
detected over 2–5 years in both cognitively preserved
and cognitively impaired patients.30–32 In contrast, one
study reported minimal cognitive decline over four
years.33
Published data suggest that the remission of cogni-
tive symptoms is unlikely,1,9 but we found signiﬁcant
improvement in the cognitive impairment index from
baseline to year 3 with sc IFNb-1a, suggesting DMD
treatment may improve cognitive function, at least in
patients with mild physical disability. When eﬀect-size
data are considered for individual cognitive tests, pos-
itive eﬀects of both sc IFNb-1a doses were seen at year
3 for all tests, with the exception of Word-List
Generation and SDMT. Although all eﬀects were
small (the greatest Kazis’ eﬀect size was 0.39), these
equated to a signiﬁcant improvement in the global cog-
nitive impairment index over the course of the study.
Thus, small improvements in the function of individual
cognitive domains could result in a measurable
improvement in overall cognitive performance for the
patient.
The Cox regression model analyses temporal trends
in outcome variables. Therefore, in this study it enabled
us to show that the eﬀects of high-dose treatment
started earlier than those of the lower dose, and that
the size of this eﬀect increased over time. Indeed, the
eﬀects of sc IFNb-1a on cognitive function may be
more pronounced with the high-dose treatment: the
risk of cognitive impairment over three years was
reduced by 32% with the 44mcg dose compared with
the 22mcg dose. This ﬁnding was conﬁrmed by the
results of the multivariate logistic regression analysis
and the signiﬁcantly lower proportion of cognitively
impaired patients at three years with higher, rather
than lower, dose treatment. Importantly, considering
the trend towards a higher proportion of patients
with cognitive impairment at the baseline in the lower
dose group, both the regression analyses controlled for
the baseline diﬀerences between treatment groups. In
addition, most Kazis’ eﬀect sizes were numerically
greater in the IFNb-1a 44mcg group than in the
22mcg group. However, the small diﬀerences between
treatment groups detected here may not be clinically
relevant to the individual patient.
As with all longitudinal cognition studies, the possi-
ble inﬂuence of learning eﬀects34 must be considered.
To minimize learning eﬀects in our study, cognitive
function was measured using the parallel, equivalent,
versions of Rao’s battery for serial assessments,
although this may not entirely eliminate learning
eﬀects. In the absence of an untreated control group,
the presumed dose eﬀect may provide supportive evi-
dence that IFNb-1a might stabilize cognitive function.
The more pronounced eﬀect of the higher IFNb-1a
dose on cognitive decline might be taken into account
by neurologists when starting DMD treatment to delay
physical and cognitive worsening in patients with
RRMS.
The results presented must be considered after
taking into account the limitations of this study. This
was an observational study in which patients were not
randomized to treatment, but treatment was assigned at
the physician’s discretion. The study was designed and
performed in accordance with the Guidelines for Good
Clinical Practice in randomized, controlled trials, and it
has been shown that observational studies performed in
this way do not overestimate the magnitude of eﬀects
for study outcomes.35,36 Indeed, in the MS setting,
observational studies may provide similar evidence to
that obtained from Phase III trials.36
While observational studies are more reﬂective of the
clinical setting, there is the potential for selection bias
Table 4. Multivariate logistic regression analyses for the pro-
portion of patients with 3 impaired cognitive tests during the
three-year study. Baseline predictors for cognitive impairment
at three years, corrected for baseline cognitive impairment,
are shown
Logistic regression: significant predictors at baseline
Odds ratio 95% CI
Treatment with IFN beta-1a,
44mcg sc tiw
0.51 0.26–0.99
Verbal IQ 0.97 0.93–0.99
3 impaired cognitive tests 11.23 5.66–22.28
CI, confidence interval; IFN, interferon; IQ, intelligence quotient; sc,
subcutaneously; tiw, three times weekly.
74 Multiple Sclerosis 16(1)
 by Giuseppe Salemi on April 25, 2012msj.sagepub.comDownloaded from 
towards treatment groups. Although treatment groups
were well balanced at the baseline, a non-signiﬁcant
diﬀerence in baseline cognitive function was seen
between groups. However, baseline cognitive perfor-
mance was not an inﬂuential factor in the treatment
decision-making process due to the lack of data regard-
ing the cognitive eﬀects of DMD treatment in patients
with MS at the start of the study. We used the Cox
proportional-hazards model to control for such diﬀer-
ences, but other baseline diﬀerences that were not
assessed could exist between the two groups. In addi-
tion, with the exception of the verbal IQ score, baseline
patient demographics and disease and NPS character-
istics did not diﬀer between those patients who contin-
ued treatment for three years and those who
discontinued treatment early. This diﬀerence in the
baseline verbal IQ score was not responsible for the
diﬀerence in cognitive performance at three years
between the two treatment groups and did not inﬂuence
the overall results of the study.
The sample size may aﬀect the study outcomes, as
the three-year results in this report are from a sub-
cohort of patients recruited to the study. As no impu-
tation method was used for missing data, it is not
known how the lack of these data aﬀected the study
results. Although high discontinuation rates can be a
problem for observational studies, the proportion of
patients who completed this study (72%) is comparable
with data from other clinical trials. In the Phase III
PRISMS (Prevention of Relapses and disability by
IFNb-1a Subcutaneously in Multiple Sclerosis) study,
the total study-completion rate for patients receiving sc
IFNb-1a was 81% (302/373) over four years.28 In addi-
tion, patients receiving sc IFNb-1b or im IFNb-1a were
excluded from the study due to the small patient num-
bers in these treatment groups. The dropout rate was
particularly high (79.7%) among patients receiving im
IFNb-1a. Considering that over 50% of patients in this
treatment group experienced relapses in the ﬁrst 6–12
months of the study (data not shown), it is possible to
speculate that perceived lack of eﬃcacy and the general
belief that higher and more frequent IFNb therapies are
more eﬀective than lower-dose, less-frequent treatment
regimens may have contributed to this observation.
Additional limitations to this study are common to
cognition studies in MS. The assessment and deﬁnition
of cognitive function in patients with MS has yet to be
standardized. Here, we used a validated assessment tool
and a conservative deﬁnition of ‘cognitive impairment’,
based on impairment in at least three cognitive tests,7
with impairment on tests deﬁned as 1 SD below nor-
mative Italian values. Furthermore, it has been sug-
gested that cognitive changes occur too slowly to be a
useful endpoint in studies of DMDs,37 although our
results do not support this view.
Few studies have investigated the eﬀects of DMDs
on cognitive function in patients with MS, and results
are inconclusive. In a prospective, placebo-controlled
trial, im IFNb-1a, 30mcg qw, was shown to have pro-
tective eﬀects on the cognitive domains most commonly
aﬀected in MS over two years of treatment; however,
learning eﬀects were reported.34 The cognitive beneﬁts
of high dose sc IFNb-1b have also been reported fol-
lowing two and four years of treatment,38 and after one
year, independent of eﬀects on clinical disease mea-
sures.39 Glatiramer acetate has not been shown to
have cognitive beneﬁts.40
How IFNb-1a may protect against cognitive decline
is unclear. Small but consistent correlations between
cognitive function and MRI disease measures have
been reported,1,15 suggesting that inhibition of inﬂam-
mation and lesion development may also preserve cog-
nitive function. Another possibility is that IFNb may
increase the production of neurotrophic factors that
protect against damage due to disease processes; the
IFNb-induced production of brain-derived neuro-
trophic factor41 and nerve growth factor have been
demonstrated.42
The results of our study conﬁrm that cognitive
impairment is a substantial problem, even in patients
with only mild physical disability: over half of all
patients had impaired performance on at least one cog-
nitive test, despite the fact that this patient cohort
included only patients with ‘mild’ physical disability.
The high incidence of cognitive impairment at the base-
line, and the conﬁrmation that this is a risk factor for
ongoing cognitive impairment in later years,31 demon-
strates the importance of cognitive assessment in
patients with early MS. Identifying patients with, or
at risk of, cognitive decline could enable therapeutic
intervention, but treatment options are currently lim-
ited to symptomatic therapies9,43 and acetylcholinester-
ase inhibitors,44 although the clinical beneﬁts of these
are yet to be conﬁrmed.
The results reported here indicate that treatment
with sc IFNb-1a may have dose-dependent cognitive
beneﬁts in mildly disabled patients with RRMS. In
addition, sc IFNb-1a was shown to achieve good dis-
ease control and was well tolerated in this cohort of
patients. Several studies have demonstrated the beneﬁ-
cial eﬀects of early treatment on clinical disease para-
meters45–47 and brain atrophy.48 Our results further
support the clinical beneﬁt of initiating higher dose sc
IFNb-1a treatment, even in patients with mild physical
disability.
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